Fluoroquinolones or fortified antibiotics for treating bacterial keratitis: Systematic review and meta-analysis of comparative studies

Canadian Journal of Ophthalmology

Volumn 47, Issue 6, 2012, Pages 493-499

  Hanet, Marie Sophie ^a,d   Jamart, Jacques ^b   Chaves, Alessandra Pinheiro ^c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CHUMont Godinne   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFALOTIN; CEFAZOLIN; CIPROFLOXACIN; FORTIFIED ANTIBIOTIC; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BACTERIAL KERATITIS; CLINICAL PROTOCOL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EPITHELIZATION; EVISCERATION; HEALING; HUMAN; MEDLINE; META ANALYSIS; MICROBIOLOGY; PERFORATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84874967112     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.09.001     Document Type: Article

References (22)

1. American Academy of Ophthalmology. Cornea/External Disease Panel. Bacterial keratitis. Preferred Practice Patterns. Limited revision Oct. 2011. Available at www.aao.org/ppp. Accessed November 1, 2012.
2. Fong CF, Tseng CH, Hu FR, et al. Clinical characteristics of microbial keratitis in a university hospital in Taiwan. Am J Ophthalmol. 2004;137:329-36.
3. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003;87:834-8.
4. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-5.
5. O'Brien TP, Maguire MG, Ne Fink, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995;113:1257-65.
6. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996;103:1854-62.
7. Pavesio C, Morlet N, Allan B, et al. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. The Ofloxacin Study Group. Ophthalmology. 1997;104:1902-9.
8. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye (Lond.) 1999;13:744-7.
9. Erjongmanee S, Kasetsuwan N, Phusitphoykai N, et al. Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. J Med Assoc Thai. 2004;87:S83-90.
10. Constantinou M, Daniell M, Snibson GR, et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis. A randomized clinical trial. Ophthalmology. 2007;114:1622-9.
11. Shah VM, Tandon R, Satpathy G, et al. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers. Cornea. 2010;29:751-7.
12. Kasetsuwan N, Tanthuvanit P, Reinprayoon U. The efficacy and safety of 0.5% levofloxacin versus fortified cefazolin and amikacin ophthalmic solution for the treatment of suspected and culture proven cases of infectious bacterial keratitis: a comparative study. Asian Biomedicine. 2011;5:77-83.
13. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am JOphthalmol. 1991;112:34S-47S.
14. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% ciproflox-acin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch Ophthalmol. 1993;111:1210-8.
15. Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am JOphthalmol. 1993;115:471-7.
16. Ly CN, Pham JN, Badenoch PR, et al. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluor-oquinolones and gentamicin plus cephalothin. Clin Exp Ophthal-mol. 2006;34:44-5.
17. Gangopadhyay N, Daniell M, Weih L, Taylor HR. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br JOphtalmol. 2000;84:378-84.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
19. Mallari PL, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am JOphthalmol. 2001;131:131-3.
20. Fong CF, Hu FR, Tseng CH, et al. Antibiotic susceptibility of bacterial isolates from bacterial keratitis cases in a university hospital in Taiwan. Am JOphthalmol. 2007;144:682-9.
21. Lin CP, Boehnke M. Effect of fortified antibiotic solutions on corneal epithelial wound healing. Cornea. 2000;19:204-6.
22. Willcox MDP. Review of resistance of ocular isolates of Pseudo-monas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins. Clin Exp Optom. 2011;94:161-8.